Anti-TNF alpha antibodies which selectively inhibit TNF alpha signalling through the p55R
View Patent ↗The present invention provides anti-TNFα antibodies which selectively inhibit TNFα signalling through the p55R. In particular the present invention provides anti-TNFα antibodies which selectively inhibit TNFα signalling through the p55R relative to the p75R.
1. An anti-TNFα antibody or a fragment thereof that selectively binds TNFα, each comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises the sequence given in SEQ ID NO:9 for CDR-H1, the sequence given in SEQ ID NO:10 or SEQ ID NO:21 for CDR-H2 and the sequence given in SEQ ID NO:11 for CDR-H3 and wherein the light chain variable domain comprises the sequence given in SEQ ID NO:12 for CDR-L1, the sequence given in SEQ ID NO:13 for CDR-L2 and the sequence given in SEQ ID NO:14 for CDR-L3.
2. The anti-TNFα antibody or fragment thereof according to claim 1 comprising
(a) a heavy chain comprising SEQ ID NO:6 or SEQ ID NO:20 and
(b) a light chain comprising SEQ ID NO:8.
3. The antibody according to claim 1 , wherein the antibody or fragment thereof is a CDR-grafted antibody.
4. The antibody according to claim 1 .
5. The antibody according to claim 2 .
6. The fragment according to claim 1 wherein the fragment is an Fab, Fab′, F(ab′) 2 , or scFv fragment.
7. The antibody or fragment thereof according to claim 1 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).
8. The antibody according to claim 7 .
9. A pharmaceutical composition comprising an anti-TNFα antibody according to claim 1 and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the fragment according to claim 1 and a pharmaceutically acceptable carrier.